Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 11,408 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Hypertension
Interventions: Self-Guided M.A.P. BP Improvement Program, Full Support M.A.P. BP Improvement Program; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,238,835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 24
States / cities: Crescent City, California • Eureka, California • Los Angeles, California + 15 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: etoposide, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 62
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 38 more

Conditions: Andropause
Interventions: AndroGel® (testosterone gel), Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older · Male only
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more

Conditions: Pediatric Acute Myelogenous Leukemia (AML)
Interventions: Decitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Phoenix, Arizona • Madera, California • Aurora, Colorado + 14 more

Conditions: Sarcoma
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 99
States / cities: Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more

Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions: Tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 45
States / cities: Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more

Conditions: Relapsed/Refractory Acute Leukemia
Interventions: Revumenib; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 6 Months and older
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: Perennial Allergic Rhinitis
Interventions: 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 43
States / cities: Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more

Conditions: Asthma
Interventions: Spirometry Fundamentals™ Training CD; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer, Quality of Life, Anxiety, Depression, Hope, Coping Skills, Communication
Interventions: Promoting Resilience in Stress Management (PRISM); Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Years to 24 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more

Conditions: Diabetic Retinopathy
Interventions: Laser Photocoagulation, Bevacizumab; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more

Conditions: Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions: Ibrutinib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions: Elinzanetant (BAY3427080), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 55
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more

Conditions: Transient Ischemic Attack, Thromboembolic Stroke, Stroke Prevention
Interventions: EndoTex™ NexStent™, Filter Wire EZ™; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 15
States / cities: Phoenix, Arizona • Mountain View, California • Newport Beach, California + 10 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: CC-91633; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Colorectal Cancer
Interventions: olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • Palm Springs, California • Aurora, Colorado + 5 more

Conditions: Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions: Stem Cell Transplantation, CD34 selection; Procedure · Device
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Cancer
Interventions: surgical procedure, radiation therapy, stereotactic radiosurgery; Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 240
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: Alzheimer Disease, Dementia
Interventions: STAR-C Virtual Training and Follow-up (STAR-VTF); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Lynnwood, Washington • Seattle, Washington

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 34 more

Conditions: Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Miami, Florida • Iowa City, Iowa • Boston, Massachusetts + 6 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Tropifexor (LJN452), Cenicriviroc (CVC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more

Search by objective public record fields.

Improving BP Control in Diverse Populations Using BP MAP

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

The Testosterone Trials in Older Men

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Expanded Access Program for Revumenib

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

Trial of Spirometry Fundamentals™ in the Primary Care Setting

The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

Cultural Adaptation of a Behavioral Intervention for Latino Caregivers

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

Spastic Paraplegia - Centers of Excellence Research Network

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis